370 results on '"Gabrielle, Pierre-Henry"'
Search Results
2. Initial response and 12-month outcomes after commencing dexamethasone or vascular endothelial growth factor inhibitors for retinal vein occlusion in the FRB registry
Catalog
Books, media, physical & digital resources
3. Long-term intake of Lactobacillushelveticus enhances bioavailability of omega-3 fatty acids in the mouse retina
4. Outcomes and Baseline Predictors of Failure in Primary Standalone Xen45 Gel Stent versus Trabeculectomy for Glaucoma
5. Severe Intraocular Inflammation After Intravitreal Injection of Faricimab: A Single-Site Case Series of Six Patients
6. Does HbA1c Level or Glomerular Filtration Rate Affect the Clinical Response to Endothelial Growth Factor Therapy (Ranibizumab or Aflibercept) in Diabetic Macular Edema? A Real-Life Experience
7. Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion
8. Study protocol of OmegaROP-2 prospective study: expression of placental fatty acid receptors in preterm newborns with retinopathy of prematurity
9. From randomised controlled trials to real-world data: Clinical evidence to guide management of diabetic macular oedema
10. Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents, and Age-Related Macular Degeneration Study: A Randomized Controlled Trial for Submacular Hemorrhage Secondary to Age-Related Macular Degeneration
11. Update on Retinal Vein Occlusion
12. Comprehensive mass spectrometry lipidomics of human biofluids and ocular tissues
13. Diabetic retinopathy in the pediatric population: Pathophysiology, screening, current and future treatments
14. Polypoidal Choroidal Vasculopathy Based on Non-ICGA Criteria in White Patients With Neovascular Age-Related Macular Degeneration
15. Incidence of Rhegmatogenous Retinal Detachment Following Macular Surgery in France Between 2006 and 2016
16. Intraocular Pressure Changes After Intravitreal Fluocinolone Acetonide Implant: Results from Four European Countries
17. Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
18. Two-year outcomes of Xen 45 gel stent implantation in patients with open-angle glaucoma: real-world data from the Fight Glaucoma Blindness registry.
19. The gut microbiota in retinal diseases
20. One-year anti-VEGF therapy outcomes in diabetic macular edema based on treatment intensity: Data from the FRB! registry
21. Presumed Natural History of Combined Hamartoma of the Retina and Retinal Pigment Epithelium
22. Mucosal-associated invariant T cells in Giant Cell Arteritis
23. Three-Year Outcomes of VEGF Inhibitors in Naive Branch Retinal Vein Occlusion
24. Subclinical subretinal fluid detectable only by optical coherence tomography in choroidal naevi—the SON study
25. Intraocular Pressure Changes and Vascular Endothelial Growth Factor Inhibitor Use in Various Retinal Diseases: Long-Term Outcomes in Routine Clinical Practice: Data from the Fight Retinal Blindness! Registry
26. Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry
27. Long-term intake of Lactobacillus helveticus enhances bioavailability of omega-3 fatty acids in the mouse retina
28. European Unmet Needs in the Management of Neovascular Age-Related Macular Degeneration in Daily Practice
29. Plasma fatty acids and primary open-angle glaucoma in the elderly: the Montrachet population-based study
30. Cystoid maculopathy is a frequent feature of Cohen syndrome-associated retinopathy
31. Peripapillary Versus Macular Combined Hamartoma of the Retina and Retinal Pigment Epithelium: Imaging Characteristics
32. Association between anatomical and clinical outcomes of neovascular age-related macular degeneration treated with anti-VEGF
33. Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study
34. EPIDEMIOLOGY OF VITREOMACULAR INTERFACE ABNORMALITIES USING MACULAR SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY IN AN ELDERLY POPULATION (THE MONTRACHET STUDY)
35. A Retinal Oct-Angiography and Cardiovascular STAtus (RASTA) Dataset of Swept-Source Microvascular Imaging for Cardiovascular Risk Assessment
36. 12-month outcomes of treatment-naïve retinal vein occlusion initially treated with either dexamethasone implants or vascular endothelial growth factor inhibitors: Data from the Fight Retinal Blindness! registry
37. Cholesterol metabolism and glaucoma: Modulation of Muller cell membrane organization by 24S-hydroxycholesterol
38. Can high-dose aflibercept satisfy unmet treatment needs in diabetic macular oedema?
39. POPPER MACULOPATHY: LONG-TERM FOLLOW-UP AND CASE SERIES
40. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema
41. Antiplatelet and anticoagulant agents in vitreoretinal surgery: a prospective multicenter study involving 804 patients
42. Early Retinal Microvascular Changes Assessed with Swept-Source OCT Angiography in Type 1 Diabetes Patients without Retinopathy
43. STAR: a randomized controlled trial for submacular hemorrhage secondary to age-related macular degeneration
44. Association of lipid-lowering drugs and antidiabetic drugs with age-related macular degeneration:A meta-analysis in Europeans
45. Does HbA1c Level or Glomerular Filtration Rate Affect the Clinical Response to Endothelial Growth Factor Therapy (Ranibizumab or Aflibercept) in Diabetic Macular Edema? A Real-Life Experience
46. Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion
47. Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
48. Central retinal vein occlusion 36-month outcomes with anti-vascular endothelial growth factors: the Fight Retinal Blindness! registry
49. Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular age-related macular degeneration in daily clinical practice: data from the FRB! registry
50. Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases: Data from the Fight Retinal Blindness! Registry
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.